Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05113771 · ClinicalTrials.gov registry record · Phase 2
A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD
A Phase 2 study of Treatment-Resistant Depression, sponsored by Denovo Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 197
- Enrollment target
- 20
- Study locations
NCT05113771 is a Phase 2 study of Treatment-Resistant Depression that has completed, run by Denovo Biopharma. The registered enrollment target is 197 participants, below the 370-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (47% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT05113771, a Phase 2 study of Treatment-Resistant Depression, has completed, sponsored by Denovo Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 197 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study was conducted as a randomized, double-blind, placebo-controlled, multi-center Phase 2b study. Approximately 180 subjects with treatment resistant depression who meet all eligibility criteria will be enrolled. The primary endpoint is to demonstrate liafensine is superior to placebo in DGM4 positive patients with TRD.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Liafensine
Study Locations (20)
California
- Collaborative Neuroschience Research, LLC - Garden Grove
- Behavioral Research Specialists, LLC - Glendale
- Sunwise Clinical Research, LLC. - Lafayette
- Excell Research - Oceanside
- Anderson Clinical Reseach - Redlands
- Schuster Medical Research Institute - Sherman Oaks
- Collaborative Neuroscience Research, LLC - Torrance
- Pacific Clinical Research Management Group - Upland
Florida
- Clinical Research of Brandon, LLC - Brandon
- Access Research Institute - Brooksville
- The Medicine Medical Research - Hollywood
- Nuovida Research Center - Miami
- SG Research, LLC - Miami
- Aqualane Clinical Research - Naples
- Clinical Neuroscience Solutions, Inc. - Orlando
Georgia
- CenExel Atlanta Center for Medical Research - Atlanta
- Psych Atlanta, PC - Marietta
Alabama
- University of Alabama at Birmingham - Huntsville
Arizona
- Alea Research - Phoenix
Illinois
- Revive Research Institute, Inc - Elgin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2022-06-29 |
| Est. Completion | 2024-03-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05113771
The ClinicalTrials.gov registry entry for NCT05113771 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 197 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 370-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (47% lower). The listed sponsor is Denovo Biopharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Treatment-Resistant Depression appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05113771 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT05113771 about?
NCT05113771 is a clinical study titled "A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD". This study was conducted as a randomized, double-blind, placebo-controlled, multi-center Phase 2b study. Approximately 180 subjects with treatment resistant depression who meet all eligibility criteria will be enrolled. The primary endpoint is to demonstrate liafensine is superior to placebo in DGM4...
What is the current status of trial NCT05113771?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 197 participants. The study started on 2022-06-29. Estimated completion is 2024-03-05.
What conditions does trial NCT05113771 study?
This clinical trial studies the following conditions: Treatment-Resistant Depression.
What interventions are being tested in trial NCT05113771?
The interventions under investigation include: Placebo (DRUG), Liafensine (DRUG).
Who is sponsoring clinical trial NCT05113771?
This trial is sponsored by Denovo Biopharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05113771 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Treatment-Resistant Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
RECRUITING · Phase 2
-
Psilocybin rTMS for Treatment Resistant Depression
RECRUITING · Phase 2
-
Antidepressant Effects of Nitrous Oxide
RECRUITING · Phase 2
-
Mindfulness Engaged Neurostimulation for Depression
RECRUITING · Phase 2
-
Neural and Antidepressant Effects of Propofol
ACTIVE NOT RECRUITING · Phase 2
-
Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.